Quarterly ResultAug 5, 2026, 04:30 PM
Arcutis Q2 Product Revenue +59.3% to $129.9M; Net Income $15.0M
AI Summary
Arcutis Biotherapeutics reported strong second-quarter 2026 financial results, with product revenue, net, increasing 59.3% to $129.9 million. The company achieved a net income of $15.0 million, or $0.11 diluted earnings per share, a significant improvement from a net loss in the prior year period. For the six months ended June 30, 2026, product revenue, net, grew 59.6% to $235.3 million, resulting in a net income of $3.7 million. The company also highlighted continued commercial launches and regulatory progress for its ZORYVE product line across various indications and age groups.
Key Highlights
- Q2 2026 product revenue, net, increased 59.3% to $129.9 million.
- Reported Q2 2026 net income of $15.0 million, compared to a $15.9 million net loss in Q2 2025.
- Diluted EPS for Q2 2026 was $0.11, up from $(0.13) in Q2 2025.
- Six-month product revenue, net, grew 59.6% to $235.3 million.
- Cash, cash equivalents, restricted cash, and marketable securities totaled $238.9 million.
- ZORYVE foam Q2 revenue reached $67.4 million, up from $39.2 million.
- ZORYVE cream 0.3% Q2 revenue was $35.3 million, up from $27.7 million.
- Company believes existing capital resources are sufficient for at least 12 months.
Price Impact
More from ARQT